FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Nicholas Restifo

Research Profile

Living Beings

Anatomy

Procedures

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
L Zhang; Pawel Muranski; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Z Yu; Richard A Morgan
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Shicheng Yang; Zhiya Yu; Ling Zhang; Luca Gattinoni; Yun Ji; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Pawel Muranski; Nicholas P Restifo
Essentials of Th17 cell commitment and plasticity.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Nicholas Restifo (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: L Zhang; Pawel Muranski; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Z Yu; Richard A Morgan
Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy.
Gene therapy 2013;20(5):575-80.
2013: Shicheng Yang; Zhiya Yu; Ling Zhang; Luca Gattinoni; Yun Ji; Nicholas P Restifo; Steven A Rosenberg; Richard A Morgan
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Cancer immunology, immunotherapy : CII 2013;62(4):727-36.
2013: Pawel Muranski; Nicholas P Restifo
Essentials of Th17 cell commitment and plasticity.
Blood 2013;121(13):2402-14.
2013: Joseph G Crompton; Mahendra S Rao; Nicholas P Restifo
Memoirs of a reincarnated T cell.
Cell stem cell 2013;12(1):6-8.
2013: Ken-Ichi Hanada; Nicholas P Restifo
Double or nothing on cancer immunotherapy.
Nature biotechnology 2013;31(1):33-4.
2012: Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
Sorting through subsets: which T-cell populations mediate highly effective adoptive immunotherapy?
Journal of immunotherapy (Hagerstown, Md. : 1997) 2012;35(9):651-60.
2012: Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Paths to stemness: building the ultimate antitumour T cell.
Nature reviews. Cancer 2012;12(10):671-84.
2012: Anran Wang; Tamara Aghamolla; Melissa M Alvarez-Downing; Smita Chandran; Yu Chiu; Mark E Dudley; Chyi-Chia Richard Lee; Thomas Li; Biman C Paria; Nicholas P Restifo; STEVEN ROSENBERG; Syed A Shah; Sanmeet Singh; Udai S Kammula
The stoichiometric production of IL-2 and IFN-γ mRNA defines memory T cells that can self-renew after adoptive transfer in humans.
Science translational medicine 2012;4(149):149ra120.
2012: Weiping Zou; Nicholas P Restifo
Nine lives for TH9s?
Nature medicine 2012;18(8):1177-8.
2012: Nicholas P Restifo; Mark E Dudley; STEVEN ROSENBERG
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nature reviews. Immunology 2012;12(4):269-81.
2012: Dhanalakshmi Chinnasamy; Sid P Kerkar; Richard A Morgan; Nicholas P Restifo; Zhiya Yu; Ling Zhang; STEVEN ROSENBERG
Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(6):1672-83.
2012: David F Stroncek; Jeffrey S Miller; Gustavo Mostoslavsky; John O'Shea; Daniel J Powell; Mahendra S Rao; Nicholas P Restifo; STEVEN ROSENBERG; Carolina Berger; Martin A Cheever; Richard W Childs; Mark E Dudley; Peter Flynn; Luca Gattinoni; James R Heath; Michael Kalos; Francesco M Marincola; Cornelis J M Melief
New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer.
Journal of translational medicine 2012;10():48.
2011: Yun Ji; Christopher A Klebanoff; Francesco M Marincola; Pawel Muranski; Douglas Palmer; Zoltan Pos; Mahadev Rao; Robert N Reger; Nicholas P Restifo; David S Schrump; Madhusudhanan Sukumar; Ena Wang; Zhiya Yu; Zachary A Borman; Luca Gattinoni
Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells.
Nature immunology 2011;12(12):1230-7.
2011: Sid P Kerkar; Anthony J Leonardi; Francesco M Marincola; Richard A Morgan; Pawel Muranski; Robert N Reger; STEVEN ROSENBERG; Giorgio Trinchieri; Ena Wang; Zhiya Yu; Dhanalakshmi Chinnasamy; Romina S Goldszmid; Nicholas P Restifo
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors.
The Journal of clinical investigation 2011;121(12):4746-57.
2011: Luca Gattinoni; Emma Gostick; Yun Ji; Carl H June; Enrico Lugli; Francesco M Marincola; Chrystal M Paulos; Zoltan Pos; David A Price; Máire F Quigley; Jorge Almeida; Carmine Carpenito; Daniel C Douek; Mario Roederer; Ena Wang; Zhiya Yu; Nicholas P Restifo
A human memory T cell subset with stem cell-like properties.
Nature medicine 2011;17(10):1290-7.
2011: Gangqing Hu; Suming Huang; Daniel Northrup; Nicholas P Restifo; Gang-Qing Hu; Qingsong Tang; River Ybarra; Kairong Cui; Luca Gattinoni; Keji Zhao
Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1.
Genome research 2011;21(10):1650-8.
2011: Christopher A Klebanoff; Pawel Muranski; Douglas Palmer; Zachary A Borman; Steven E Finkelstein; Luca Gattinoni; Christian S Hinrichs; Yun Ji; Sid P Kerkar; STEVEN ROSENBERG; Christopher D Scott; Nicholas P Restifo
Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(16):5343-52.
2011: STEVEN ROSENBERG; Richard M Sherry; Seth M Steinberg; Donald E White; John R Wunderlich; James C Yang; Marybeth S Hughes; Udai S Kammula; Carolyn M Laurencot; Kathleen E Morton; Giao Q Phan; Nicholas P Restifo; Paul F Robbins; Deborah Citrin; Mark E Dudley
Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4550-7.
2011: Sid P Kerkar; Luis Sanchez-Perez; Shicheng Yang; Zachary A Borman; Pawel Muranski; Yun Ji; Dhanalakshmi Chinnasamy; Andrew Kaiser; Christian S Hinrichs; Christopher A Klebanoff; Christopher D Scott; Luca Gattinoni; Richard A Morgan; STEVEN ROSENBERG; Nicholas P Restifo
Genetic engineering of murine CD8+ and CD4+ T cells for preclinical adoptive immunotherapy studies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2011;34(4):343-52.
2011: Shicheng Yang; Gattinoni Luca; Fang Liu; Yun Ji; Zhiya Yu; Nicholas P Restifo; STEVEN ROSENBERG; Luca Gattinoni; Richard A Morgan
In vitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking in vivo antigen-experienced cells.
Cancer immunology, immunotherapy : CII 2011;60(5):739-49.
2011: Ling Zhang; Sid P Kerkar; Zhiya Yu; Zhili Zheng; Shicheng Yang; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(4):751-9.
2011: Paul F Robbins; Richard A Morgan; Steven A Feldman; James C Yang; Richard M Sherry; Mark E Dudley; John R Wunderlich; Azam V Nahvi; Lee Helman; CRYSTAL MACKALL; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Mark Raffeld; Chyi-Chia Richard Lee; Catherine L Levy; Yong F Li; Mona El-Gamil; Susan L Schwarz; Carolyn Laurencot; STEVEN ROSENBERG
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(7):917-24.
2011: Maria R Parkhurst; James C Yang; Russell C Langan; Mark E Dudley; Debbie-Ann N Nathan; Steven A Feldman; Jeremy L Davis; Richard A Morgan; Maria J Merino; Richard M Sherry; Marybeth S Hughes; Udai S Kammula; Giao Q Phan; Ramona M Lim; Stephen A Wank; Nicholas P Restifo; Paul F Robbins; Carolyn M Laurencot; STEVEN ROSENBERG
T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.
Molecular therapy : the journal of the American Society of Gene Therapy 2011;19(3):620-6.
2011: Christian S Hinrichs; Zachary A Borman; Luca Gattinoni; Zhiya Yu; William R Burns; Jianping Huang; Christopher A Klebanoff; Laura A Johnson; Sid P Kerkar; Shicheng Yang; Pawel Muranski; Douglas Palmer; Christopher D Scott; Richard A Morgan; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy.
Blood 2011;117(3):808-14.
2011: Nachimuthu Chinnasamy; Jennifer A Wargo; Zhiya Yu; Mahadev Rao; Timothy L Frankel; John P Riley; Jenny J Hong; Maria R Parkhurst; Steven A Feldman; David S Schrump; Nicholas P Restifo; Paul F Robbins; STEVEN ROSENBERG; Richard A Morgan
A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Journal of immunology (Baltimore, Md. : 1950) 2011;186(2):685-96.
2011: Maria Libera Ascierto; Paolo A Ascierto; Davide Bedognetti; Nanhai G Chen; Giovanni Di Pasquale; Sharon Adams; Zoltan Pos; Jennifer Reinboth; Nicholas P Restifo; Fabio Rossano; Rahul Roychoudhuri; David F Stroncek; Aladar A Szalay; lorenzo uccellini; Ena Wang; Andrea Worschech; Zhiya Yu; Francesco M Marincola
Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68.
BMC cancer 2011;11():451.
2011: Christopher A Klebanoff; Nicolas Acquavella; Zhiya Yu; Nicholas P Restifo
Therapeutic cancer vaccines: are we there yet?
Immunological reviews 2011;239(1):27-44.
2010: Mark E Dudley; Colin A Gross; Michelle M Langhan; Marcos R Garcia; Richard M Sherry; James C Yang; Giao Q Phan; Udai S Kammula; Marybeth S Hughes; Deborah Citrin; Nicholas P Restifo; John R Wunderlich; Peter A Prieto; Jenny J Hong; Russell C Langan; Daniel A Zlott; Kathleen E Morton; Donald E White; Carolyn M Laurencot; STEVEN ROSENBERG
CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(24):6122-31.
2010: Nicholas P Restifo
Can antitumor immunity help to explain "oncogene addiction"?
Cancer cell 2010;18(5):403-5.
2010: James N Kochenderfer; Zhiya Yu; Dorina Frasheri; Nicholas P Restifo; STEVEN ROSENBERG
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
Blood 2010;116(19):3875-86.
2010: Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; STEVEN ROSENBERG
Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.
The Journal of clinical investigation 2010;120(11):3953-68.
2010: Luca Gattinoni; Yun Ji; Nicholas P Restifo
Wnt/beta-catenin signaling in T-cell immunity and cancer immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4695-701.
2010: Sid P Kerkar; Pawel Muranski; Andrew Kaiser; Andrea Boni; Luis Sanchez-Perez; Zhiya Yu; Douglas Palmer; Robert N Reger; Zachary A Borman; Ling Zhang; Richard A Morgan; Luca Gattinoni; STEVEN ROSENBERG; Giorgio Trinchieri; Nicholas P Restifo
Tumor-specific CD8+ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts.
Cancer research 2010;70(17):6725-34.
2010: Rajeev K Shrimali; Zhiya Yu; Marc R Theoret; Dhanalakshmi Chinnasamy; Nicholas P Restifo; STEVEN ROSENBERG
Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer.
Cancer research 2010;70(15):6171-80.
2010: STEVEN ROSENBERG; James C Yang; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Susan L Schwarz; Kathleen E Morton; Carolyn M Laurencot; Richard M Sherry
Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(6):626-9.
2010: Timothy L Frankel; William R Burns; Peter D Peng; Zhiya Yu; Dhanalakshmi Chinnasamy; Jennifer A Wargo; Zhili Zheng; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Journal of immunology (Baltimore, Md. : 1950) 2010;184(11):5988-98.
2010: Weiping Zou; Nicholas P Restifo
T(H)17 cells in tumour immunity and immunotherapy.
Nature reviews. Immunology 2010;10(4):248-56.
2010: Ying Xie; Akgül Akpinarli; Charles Maris; Edward L Hipkiss; Malcolm Lane; Eun-Kyung M Kwon; Pawel Muranski; Nicholas P Restifo; Paul A Antony
Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
The Journal of experimental medicine 2010;207(3):651-67.
2010: Sergio Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
The Journal of experimental medicine 2010;207(3):637-50.
2010: Lukas Flatz; Ahmed N Hegazy; Andreas Bergthaler; Admar Verschoor; Christina Claus; Marylise Fernandez; Luca Gattinoni; Susan Johnson; Florian Kreppel; Stefan Kochanek; Maries van den Broek; Andreas Radbruch; Frédéric Lévy; Paul-Henri Lambert; Claire-Anne Siegrist; Nicholas P Restifo; Max Löhning; Adrian F Ochsenbein; Gary Nabel; Daniel D Pinschewer
Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity.
Nature medicine 2010;16(3):339-45.
2010: Claudia Wrzesinski; Chrystal M Paulos; Andrew Kaiser; Pawel Muranski; Douglas Palmer; Luca Gattinoni; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2010;33(1):1-7.
2009: Luca Gattinoni; Christopher A Klebanoff; Nicholas P Restifo
Pharmacologic induction of CD8+ T cell memory: better living through chemistry.
Science translational medicine 2009;1(11):11ps12.
2009: Douglas Palmer; Nicholas P Restifo
Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.
Trends in immunology 2009;30(12):592-602.
2009: Natalia Martin-Orozco; Pawel Muranski; Yeonseok Chung; Xuexian O Yang; Tomohide Yamazaki; Sijie Lu; Patrick Hwu; Nicholas P Restifo; Willem W Overwijk; Chen Dong
T helper 17 cells promote cytotoxic T cell activation in tumor immunity.
Immunity 2009;31(5):787-98.
2009: Christian S Hinrichs; Zachary A Borman; Lydie Cassard; Luca Gattinoni; Rosanne Spolski; Zhiya Yu; Luis Sanchez-Perez; Pawel Muranski; Steven J Kern; Carol Logun; Douglas Palmer; Yun Ji; Robert N Reger; Warren J Leonard; Robert L Danner; STEVEN ROSENBERG; Nicholas P Restifo
Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(41):17469-74.
2009: Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Douglas Palmer; Luca Gattinoni; Nicholas P Restifo
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Blood 2009;114(9):1776-83.
2009: Christian S Hinrichs; Andrew Kaiser; Chrystal M Paulos; Lydie Cassard; Luis Sanchez-Perez; Bianca Heemskerk; Claudia Wrzesinski; Zachary A Borman; Pawel Muranski; Nicholas P Restifo
Type 17 CD8+ T cells display enhanced antitumor immunity.
Blood 2009;114(3):596-9.
2009: Laura A Johnson; Richard A Morgan; Mark E Dudley; Lydie Cassard; James C Yang; Marybeth S Hughes; Udai S Kammula; Richard E Royal; Richard M Sherry; John R Wunderlich; Chyi-Chia R Lee; Nicholas P Restifo; Susan L Schwarz; Alexandria P Cogdill; Rachel J Bishop; Hung Kim; Carmen C Brewer; Susan F Rudy; Carter VanWaes; Jeremy L Davis; Aarti Mathur; Robert T Ripley; Debbie A Nathan; Carolyn M Laurencot; STEVEN ROSENBERG
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.
Blood 2009;114(3):535-46.
2009: Pawel Muranski; Nicholas P Restifo
Does IL-17 promote tumor growth?
Blood 2009;114(2):231-2.
2009: Luca Gattinoni; Xiao-Song Zhong; Douglas Palmer; Yun Ji; Christian S Hinrichs; Zhiya Yu; Claudia Wrzesinski; Andrea Boni; Lydie Cassard; Lindsay M Garvin; Chrystal M Paulos; Pawel Muranski; Nicholas P Restifo
Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells.
Nature medicine 2009;15(7):808-13.
2009: Eric F Tewalt; Jean M Grant; Erica L Granger; Douglas Palmer; Neal D Heuss; Dale S Gregerson; Nicholas P Restifo; Christopher C Norbury
Viral sequestration of antigen subverts cross presentation to CD8(+) T cells.
PLoS pathogens 2009;5(5):e1000457.
2009: Schumacher Ton; Nicholas P Restifo
Adoptive T cell therapy of cancer.
Current opinion in immunology 2009;21(2):187-9.
2009: Pawel Muranski; Nicholas P Restifo
Adoptive immunotherapy of cancer using CD4(+) T cells.
Current opinion in immunology 2009;21(2):200-8.
2008: Andrea Boni; Pawel Muranski; Lydie Cassard; Claudia Wrzesinski; Chrystal M Paulos; Douglas Palmer; Luca Gattinoni; Christian S Hinrichs; Chi-Chao Chan; STEVEN ROSENBERG; Nicholas P Restifo
Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers.
Blood 2008;112(12):4746-54.
2008: Mark E Dudley; James C Yang; Richard M Sherry; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Paul F Robbins; JianPing Huang; Deborah Citrin; Susan F Leitman; John R Wunderlich; Nicholas P Restifo; Armen Thomasian; Stephanie G Downey; Franz O Smith; Jacob Klapper; Kathleen E Morton; Carolyn Laurencot; Donald E White; STEVEN ROSENBERG
Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(32):5233-9.
2008: S Yang; Cyrille Cohen; P D Peng; Yangbing Zhao; L Cassard; Z Yu; Zhili Zheng; S Jones; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition.
Gene therapy 2008;15(21):1411-23.
2008: STEVEN ROSENBERG; Mark E Dudley; Nicholas P Restifo
Cancer immunotherapy.
The New England journal of medicine 2008;359(10):1072.
2008: Franz O Smith; Stephanie G Downey; Jacob A Klapper; James C Yang; Richard M Sherry; Richard E Royal; Udai S Kammula; Marybeth S Hughes; Nicholas P Restifo; Catherine L Levy; Donald E White; Seth M Steinberg; STEVEN ROSENBERG
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(17):5610-8.
2008: Sejin Ahn; Gwanghee Lee; Soo Jung Yang; Deokjae Lee; Seunghyuk Lee; Hyo Sun Shin; Min Cheol Kim; Kee Nyung Lee; Douglas Palmer; Marc R Theoret; Eric J Jenkinson; Graham Anderson; Nicholas P Restifo; Moon Gyo Kim
TSCOT+ thymic epithelial cell-mediated sensitive CD4 tolerance by direct presentation.
PLoS biology 2008;6(8):e191.
2008: Pawel Muranski; Andrea Boni; Paul A Antony; Lydie Cassard; Kari R Irvine; Andrew Kaiser; Chrystal M Paulos; Douglas Palmer; Christopher E Touloukian; Krzysztof Ptak; Luca Gattinoni; Claudia Wrzesinski; Christian S Hinrichs; Keith W Kerstann; Lionel Feigenbaum; Chi-Chao Chan; Nicholas P Restifo
Tumor-specific Th17-polarized cells eradicate large established melanoma.
Blood 2008;112(2):362-73.
2008: Douglas Palmer; Chi-Chao Chan; Luca Gattinoni; Claudia Wrzesinski; Chrystal M Paulos; Christian S Hinrichs; Daniel J Powell; Christopher A Klebanoff; Steven E Finkelstein; Robert Fariss; Zhiya Yu; Robert B Nussenblatt; STEVEN ROSENBERG; Nicholas P Restifo
Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity.
Proceedings of the National Academy of Sciences of the United States of America 2008;105(23):8061-6.
2008: Christian S Hinrichs; Rosanne Spolski; Chrystal M Paulos; Luca Gattinoni; Keith W Kerstann; Douglas Palmer; Christopher A Klebanoff; STEVEN ROSENBERG; Warren J Leonard; Nicholas P Restifo
IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy.
Blood 2008;111(11):5326-33.
2008: Beatrice Bolinger; Philippe Krebs; Yinghua Tian; Daniel Engeler; Elke Scandella; Simone Miller; Douglas Palmer; Nicholas P Restifo; Pierre-Alain Clavien; Burkhard Ludewig
Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen.
Blood 2008;111(9):4588-95.
2008: STEVEN ROSENBERG; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Nature reviews. Cancer 2008;8(4):299-308.
2008: John D Abad; Claudia Wrzensinski; Willem W Overwijk; Moniek A De Witte; Annelies Jorritsma; Cary Hsu; Luca Gattinoni; Cyrille Cohen; Chrystal M Paulos; Douglas Palmer; John B A G Haanen; Schumacher Ton; STEVEN ROSENBERG; Nicholas P Restifo; Richard A Morgan
T-cell receptor gene therapy of established tumors in a murine melanoma model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008;31(1):1-6.
2007: Oleg Y Borbulevych; Francis K Insaidoo; Tiffany K Baxter; Daniel J Powell; Laura A Johnson; Nicholas P Restifo; Brian M Baker
Structures of MART-126/27-35 Peptide/HLA-A2 complexes reveal a remarkable disconnect between antigen structural homology and T cell recognition.
Journal of molecular biology 2007;372(5):1123-36.
2007: Chrystal M Paulos; Andrew Kaiser; Claudia Wrzesinski; Christian S Hinrichs; Lydie Cassard; Andrea Boni; Pawel Muranski; Luis Sanchez-Perez; Douglas Palmer; Zhiya Yu; Paul A Antony; Luca Gattinoni; STEVEN ROSENBERG; Nicholas P Restifo
Toll-like receptors in tumor immunotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(18 Pt 1):5280-9.
2007: Chrystal M Paulos; Claudia Wrzesinski; Andrew Kaiser; Christian S Hinrichs; Marcello Chieppa; Lydie Cassard; Douglas Palmer; Andrea Boni; Pawel Muranski; Zhiya Yu; Luca Gattinoni; Paul A Antony; STEVEN ROSENBERG; Nicholas P Restifo
Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.
The Journal of clinical investigation 2007;117(8):2197-204.
2007: Yangbing Zhao; Maria R Parkhurst; Zhili Zheng; Cyrille Cohen; John P Riley; Luca Gattinoni; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.
Cancer research 2007;67(6):2425-9.
2007: Claudia Wrzesinski; Chrystal M Paulos; Luca Gattinoni; Douglas Palmer; Andrew Kaiser; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells.
The Journal of clinical investigation 2007;117(2):492-501.
2006: Pawel Muranski; Andrea Boni; Claudia Wrzesinski; Deborah Citrin; STEVEN ROSENBERG; Richard Childs; Nicholas P Restifo
Increased intensity lymphodepletion and adoptive immunotherapy--how far can we go?
Nature clinical practice. Oncology 2006;3(12):668-81.
2006: Luca Gattinoni; Anju Ranganathan; Deborah R Surman; Douglas Palmer; Paul A Antony; Marc R Theoret; David M Heimann; STEVEN ROSENBERG; Nicholas P Restifo
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Blood 2006;108(12):3818-23.
2006: Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda Rogers-Freezer; Sharon A Mavroukakis; STEVEN ROSENBERG
Cancer regression in patients after transfer of genetically engineered lymphocytes.
Science (New York, N.Y.) 2006;314(5796):126-9.
2006: Chih-Hung Lee; Takashi Kakinuma; Julia Wang; Hong Zhang; Douglas Palmer; Nicholas P Restifo; Sam T Hwang
Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases.
Molecular cancer therapeutics 2006;5(10):2592-9.
2006: Keri B Donohue; Jean M Grant; Eric F Tewalt; Douglas Palmer; Marc R Theoret; Nicholas P Restifo; Christopher C Norbury
Cross-priming utilizes antigen not available to the direct presentation pathway.
Immunology 2006;119(1):63-73.
2006: Wolfgang W Leitner; Elke Bergmann-Leitner; Leroy N Hwang; Nicholas P Restifo
Type I Interferons are essential for the efficacy of replicase-based DNA vaccines.
Vaccine 2006;24(24):5110-8.
2006: Christopher A Klebanoff; Luca Gattinoni; Nicholas P Restifo
CD8+ T-cell memory in tumor immunology and immunotherapy.
Immunological reviews 2006;211():214-24.
2006: Christian S Hinrichs; Luca Gattinoni; Nicholas P Restifo
Programming CD8+ T cells for effective immunotherapy.
Current opinion in immunology 2006;18(3):363-70.
2006: Adam D Cohen; Adi Diab; Miguel-Angel Perales; Jedd D Wolchok; Gabrielle Rizzuto; Taha Merghoub; Deonka Huggins; Cailian Liu; Mary Jo Turk; Nicholas P Restifo; Shimon Sakaguchi; Alan N Houghton
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.
Cancer research 2006;66(9):4904-12.
2006: Luca Gattinoni; Daniel J Powell; STEVEN ROSENBERG; Nicholas P Restifo
Adoptive immunotherapy for cancer: building on success.
Nature reviews. Immunology 2006;6(5):383-93.
2006: Paul A Antony; Chrystal M Paulos; Mojgan Ahmadzadeh; Akgül Akpinarli; Douglas Palmer; Noriko Sato; Andrew Kaiser; Christian S Hinrichs; Christian Heinrichs; Christopher A Klebanoff; Yutaka Tagaya; Nicholas P Restifo
Interleukin-2-dependent mechanisms of tolerance and immunity in vivo.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(9):5255-66.
2006: Willem W Overwijk; Karin E de Visser; Felicia H Tirion; Laurina A de Jong; Thijs W H Pols; Yme U van der Velden; Jasper G van den Boorn; Anna M Keller; Wim A Buurman; Marc R Theoret; Bianca Blom; Nicholas P Restifo; Ada M Kruisbeek; Robert A Kastelein; John B A G Haanen
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(9):5213-22.
2006: Kimberly R Lindsey; Linda Gritz; Richard M Sherry; Andrea Abati; Patricia A Fetsch; Lisa C Goldfeder; Monica I Gonzales; Kimberly A Zinnack; Linda Rogers-Freezer; Leah R Haworth; Sharon A Mavroukakis; Donald E White; Seth M Steinberg; Nicholas P Restifo; Dennis Panicali; STEVEN ROSENBERG; Suzanne Topalian
Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(8):2526-37.
2006: STEVEN ROSENBERG; Richard M Sherry; Kathleen E Morton; James C Yang; Suzanne Topalian; Richard E Royal; Udai S Kammula; Nicholas P Restifo; Marybeth S Hughes; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White
Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2006;29(2):224-31.
2006: Leroy N Hwang; Zhiya Yu; Douglas Palmer; Nicholas P Restifo
The in vivo expansion rate of properly stimulated transferred CD8+ T cells exceeds that of an aggressively growing mouse tumor.
Cancer research 2006;66(2):1132-8.
2006: Z Sheng Guo; Julie A Hong; Kari R Irvine; G Aaron Chen; Paul J Spiess; Yang Liu; Gang Zeng; John R Wunderlich; Dao Nguyen; Nicholas P Restifo; David S Schrump
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model.
Cancer research 2006;66(2):1105-13.
2006: Yangbing Zhao; Zhili Zheng; Cyrille Cohen; Luca Gattinoni; Douglas Palmer; Nicholas P Restifo; STEVEN ROSENBERG; Richard A Morgan
High-efficiency transfection of primary human and mouse T lymphocytes using RNA electroporation.
Molecular therapy : the journal of the American Society of Gene Therapy 2006;13(1):151-9.
2005: Li-Xin Wang; Rui Li; Guojun Yang; May Lim; Aisling O'Hara; Yiwei Chu; Fox Bernard; Nicholas P Restifo; Walter J Urba; Hong-Ming Hu
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.
Cancer research 2005;65(22):10569-77.
2005: STEVEN ROSENBERG; Richard M Sherry; Kathleen E Morton; William J Scharfman; James C Yang; Suzanne Topalian; Richard E Royal; Udai S Kammula; Nicholas P Restifo; Marybeth S Hughes; Douglas J Schwartzentruber; berman david; Susan L Schwarz; Lien T Ngo; Sharon A Mavroukakis; Donald E White; Seth M Steinberg
Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(9):6169-76.
2005: Christian S Hinrichs; Douglas Palmer; STEVEN ROSENBERG; Nicholas P Restifo
Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(6):517-24.
2005: Luca Gattinoni; Steven E Finkelstein; Christopher A Klebanoff; Paul A Antony; Douglas Palmer; Paul J Spiess; Leroy N Hwang; Zhiya Yu; Claudia Wrzesinski; David M Heimann; Charles D Surh; STEVEN ROSENBERG; Nicholas P Restifo
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells.
The Journal of experimental medicine 2005;202(7):907-12.
2005: Peter Attia; Giao Q Phan; Ajay V Maker; Michael R Robinson; Martha Quezado; James C Yang; Richard M Sherry; Suzanne Topalian; Udai S Kammula; Richard E Royal; Nicholas P Restifo; Leah R Haworth; Catherine Levy; Sharon A Mavroukakis; Geoffrey Nichol; Michael Yellin; STEVEN ROSENBERG
Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(25):6043-53.
2005: Christopher A Klebanoff; Luca Gattinoni; Parizad Torabi-Parizi; Kimberly F Kerstann; Adela R Cardones; Steven E Finkelstein; Douglas Palmer; Paul A Antony; Sam T Hwang; STEVEN ROSENBERG; Thomas Waldmann; Nicholas P Restifo
Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(27):9571-6.
2005: Luca Gattinoni; Christopher A Klebanoff; Douglas Palmer; Claudia Wrzesinski; Kimberly F Kerstann; Zhiya Yu; Steven E Finkelstein; Marc R Theoret; STEVEN ROSENBERG; Nicholas P Restifo
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
The Journal of clinical investigation 2005;115(6):1616-26.
2005: Oleg Y Borbulevych; Tiffany K Baxter; Zhiya Yu; Nicholas P Restifo; Brian M Baker
Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(8):4812-20.
2005: Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne Topalian; Nicholas P Restifo; Richard E Royal; Udai S Kammula; Donald E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; berman david; Armando C Filie; Andrea Abati; STEVEN ROSENBERG
Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2346-57.
2005: Claudia Wrzesinski; Nicholas P Restifo
Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy.
Current opinion in immunology 2005;17(2):195-201.
2005: Jehad Charo; Steven E Finkelstein; Navrose Grewal; Nicholas P Restifo; Paul F Robbins; STEVEN ROSENBERG
Bcl-2 overexpression enhances tumor-specific T-cell survival.
Cancer research 2005;65(5):2001-8.
2005: Paul A Antony; Ciriaco Piccirillo; Akgül Akpinarli; Steven E Finkelstein; Paul J Speiss; Deborah R Surman; Douglas Palmer; Chi-Chao Chan; Christopher A Klebanoff; Willem W Overwijk; STEVEN ROSENBERG; Nicholas P Restifo
CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(5):2591-601.
2005: Paul A Antony; Nicholas P Restifo
CD4+CD25+ T regulatory cells, immunotherapy of cancer, and interleukin-2.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2005;28(2):120-8.
2005: Christopher A Klebanoff; Hung T Khong; Paul A Antony; Douglas Palmer; Nicholas P Restifo
Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.
Trends in immunology 2005;26(2):111-7.
2005: Chien-Chung Chang; Michael Campoli; Nicholas P Restifo; Xinhui Wang; Soldano Ferrone
Immune selection of hot-spot beta 2-microglobulin gene mutations, HLA-A2 allospecificity loss, and antigen-processing machinery component down-regulation in melanoma cells derived from recurrent metastases following immunotherapy.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(3):1462-71.
2005: Rong Zeng; Rosanne Spolski; Steven E Finkelstein; SangKon Oh; Panu E Kovanen; Christian S Hinrichs; Cynthia A Pise-Masison; Michael F Radonovich; John N Brady; Nicholas P Restifo; Jay A Berzofsky; Warren J Leonard
Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.
The Journal of experimental medicine 2005;201(1):139-48.
2005: Nicholas P Restifo; STEVEN ROSENBERG
Use of standard criteria for assessment of cancer vaccines.
The lancet oncology 2005;6(1):3-4.
2004: Douglas Palmer; Sanjeeve Balasubramaniam; Ken-Ichi Hanada; Claudia Wrzesinski; Zhiya Yu; Shahram Farid; Marc R Theoret; Leroy N Hwang; Christopher A Klebanoff; Luca Gattinoni; Allan L Goldstein; James C Yang; Nicholas P Restifo
Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.
Journal of immunology (Baltimore, Md. : 1950) 2004;173(12):7209-16.
2004: Yanyan Lou; Gang Wang; Gregory Lizée; Grace J Kim; Steven E Finkelstein; Chiguang Feng; Nicholas P Restifo; Patrick Hwu
Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo.
Cancer research 2004;64(18):6783-90.
2004: STEVEN ROSENBERG; James C Yang; Nicholas P Restifo
Cancer immunotherapy: moving beyond current vaccines.
Nature medicine 2004;10(9):909-15.
2004: Zhiya Yu; Marc R Theoret; Christopher E Touloukian; Deborah R Surman; Scott C Garman; Lionel Feigenbaum; Tiffany K Baxter; Brian M Baker; Nicholas P Restifo
Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance.
The Journal of clinical investigation 2004;114(4):551-9.
2004: Steven E Finkelstein; David M Heimann; Christopher A Klebanoff; Paul A Antony; Luca Gattinoni; Christian S Hinrichs; Leroy N Hwang; Douglas Palmer; Paul J Spiess; Deborah R Surman; Claudia Wrzesiniski; Zhiya Yu; STEVEN ROSENBERG; Nicholas P Restifo
Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer.
Journal of leukocyte biology 2004;76(2):333-7.
2004: Wolfgang W Leitner; Leroy N Hwang; Elke Bergmann-Leitner; Steven E Finkelstein; Stephan Frank; Nicholas P Restifo
Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines.
Vaccine 2004;22(11-12):1537-44.
2004: Christopher A Klebanoff; Steven E Finkelstein; Deborah R Surman; Michael K Lichtman; Luca Gattinoni; Marc R Theoret; Navrose Grewal; Paul J Spiess; Paul A Antony; Douglas Palmer; Yutaka Tagaya; STEVEN ROSENBERG; Thomas Waldmann; Nicholas P Restifo
IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.
Proceedings of the National Academy of Sciences of the United States of America 2004;101(7):1969-74.
2003: Takashi Murakami; Adela R Cardones; Steven E Finkelstein; Nicholas P Restifo; Brenda A Klaunberg; Frank O Nestle; S Sianna Castillo; Phillip A Dennis; Sam T Hwang
Immune evasion by murine melanoma mediated through CC chemokine receptor-10.
The Journal of experimental medicine 2003;198(9):1337-47.
2003: Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; STEVEN ROSENBERG
High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens.
Journal of immunology (Baltimore, Md. : 1950) 2003;171(6):3287-95.
2003: STEVEN ROSENBERG; James C Yang; Paul F Robbins; John R Wunderlich; Patrick Hwu; Richard M Sherry; Douglas J Schwartzentruber; Suzanne Topalian; Nicholas P Restifo; Armando C Filie; Richard Chang; Mark E Dudley
Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(5):385-93.
2003: Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; STEVEN ROSENBERG; Nicholas P Restifo
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.
The Journal of experimental medicine 2003;198(4):569-80.
2003: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Suzanne Topalian; Richard M Sherry; Nicholas P Restifo; John R Wunderlich; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Linda Gritz; Dennis Panicali; Donald E White
Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(8):2973-80.
2003: Giao Q Phan; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Paul H Duray; Seth M Steinberg; James P Allison; Thomas A Davis; STEVEN ROSENBERG
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Proceedings of the National Academy of Sciences of the United States of America 2003;100(14):8372-7.
2003: Giao Q Phan; Christopher E Touloukian; James C Yang; Nicholas P Restifo; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(4):349-56.
2003: Wolfgang W Leitner; Nicholas P Restifo
DNA vaccines and apoptosis: to kill or not to kill?
The Journal of clinical investigation 2003;112(1):22-4.
2003: STEVEN ROSENBERG; James C Yang; Richard M Sherry; Patrick Hwu; Suzanne Topalian; Douglas J Schwartzentruber; Nicholas P Restifo; Leah R Haworth; Claudia A Seipp; Linda J Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White
Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen.
Human gene therapy 2003;14(8):709-14.
2003: Christopher E Touloukian; Wolfgang W Leitner; Rhonda E Schnur; Paul F Robbins; Yong Li; Scott Southwood; Alessandro Sette; STEVEN ROSENBERG; Nicholas P Restifo
Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(3):1579-85.
2003: Wolfgang W Leitner; Leroy N Hwang; Michael J deVeer; Aimin Zhou; Robert H Silverman; Bryan R G Williams; Thomas W Dubensky; Han Ying; Nicholas P Restifo
Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
Nature medicine 2003;9(1):33-9.
2002: Hung T Khong; Nicholas P Restifo
Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
Nature immunology 2002;3(11):999-1005.
2002: Yilin C Neeley; Kevin T McDonagh; Willem W Overwijk; Nicholas P Restifo; Martin G Sanda
Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC.
The Prostate 2002;53(3):183-91.
2002: J Mark Sloan; Michael H Kershaw; Christopher E Touloukian; Réjean Lapointe; Paul F Robbins; Nicholas P Restifo; Patrick Hwu
MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells.
Cancer gene therapy 2002;9(11):946-50.
2002: Mark E Dudley; John R Wunderlich; Paul F Robbins; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne Topalian; Richard M Sherry; Nicholas P Restifo; Amy M Hubicki; Michael R Robinson; Mark Raffeld; Paul H Duray; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Sharon A Mavroukakis; Donald E White; STEVEN ROSENBERG
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes.
Science (New York, N.Y.) 2002;298(5594):850-4.
2002: Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; Yong F Li; Xiaoqiang Kang; Réjean Lapointe; Patrick Hwu; STEVEN ROSENBERG; Nicholas P Restifo
Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
Cancer research 2002;62(18):5144-7.
2002: Zhiya Yu; Nicholas P Restifo
Cancer vaccines: progress reveals new complexities.
The Journal of clinical investigation 2002;110(3):289-94.
2002: Ena Wang; Lance D Miller; Galen A Ohnmacht; Simone Mocellin; Ainhoa Perez-Diez; David Petersen; Yingdong Zhao; Richard Simon; John I Powell; Esther Asaki; H Richard Alexander; Paul H Duray; Meenhard Herlyn; Nicholas P Restifo; Edison Liu; STEVEN ROSENBERG; Francesco M Marincola
Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness.
Cancer research 2002;62(13):3581-6.
2002: Helen Y Wang; Tihui Fu; Gang Wang; Gang Zeng; Donna M Perry-Lalley; James C Yang; Nicholas P Restifo; Patrick Hwu; Rongfu Wang
Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.
The Journal of clinical investigation 2002;109(11):1463-70.
2002: Paul A Antony; Nicholas P Restifo
Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
Journal of immunotherapy (Hagerstown, Md. : 1997) 2002;25(3):202-6.
2002: Nicholas P Restifo; Paul A Antony; Steven E Finkelstein; Wolfgang W Leitner; Deborah P Surman; Marc R Theoret; Christopher E Touloukian
Assumptions of the tumor 'escape' hypothesis.
Seminars in cancer biology 2002;12(1):81-6.
2002: John F Toso; Vee J Gill; Patrick Hwu; Francesco M Marincola; Nicholas P Restifo; Douglas J Schwartzentruber; Richard M Sherry; Suzanne Topalian; James C Yang; Frida Stock; Linda J Freezer; Kathleen E Morton; Claudia A Seipp; Leah R Haworth; Sharon A Mavroukakis; Donald White; Susan MacDonald; John Mao; Mario Sznol; STEVEN ROSENBERG
Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):142-52.
2002: Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Intensity of the vaccine-elicited immune response determines tumor clearance.
Journal of immunology (Baltimore, Md. : 1950) 2002;168(1):338-47.
2001: Christopher E Touloukian; Wolfgang W Leitner; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
Cancer research 2001;61(22):8100-4.
2001: Michael H Kershaw; C Hsu; W Mondesire; Linda L Parker; Gang Wang; Willem W Overwijk; Réjean Lapointe; James C Yang; Rongfu Wang; Nicholas P Restifo; Patrick Hwu
Immunization against endogenous retroviral tumor-associated antigens.
Cancer research 2001;61(21):7920-4.
2001: Willem W Overwijk; Nicholas P Restifo
B16 as a mouse model for human melanoma.
Current protocols in immunology / edited by John E. Coligan ... [et al.] 2001;Chapter 20():Unit 20.1.
2001: Nicholas P Restifo
Hierarchy, tolerance, and dominance in the antitumor T-cell response.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2001;24(3):193-4.
2000: Vincenzo Bronte; Elisa Apolloni; Anna Cabrelle; R Ronca; paolo serafini; P Zamboni; Nicholas P Restifo; Paola Zanovello
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
Blood 2000;96(12):3838-46.
2000: Nicholas P Restifo
Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
Current opinion in immunology 2000;12(5):597-603.
2000: Gang Zeng; Christopher E Touloukian; X Wang; Nicholas P Restifo; STEVEN ROSENBERG; Rongfu Wang
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.
Journal of immunology (Baltimore, Md. : 1950) 2000;165(2):1153-9.
2000: Nicholas P Restifo
Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
Nature medicine 2000;6(5):493-5.
2000: LG Charles; Y C Xie; Nicholas P Restifo; Blake J Roessler; Martin G Sanda
Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development.
World journal of urology 2000;18(2):136-42.
2000: Christopher E Touloukian; Wolfgang W Leitner; Suzanne Topalian; Yong F Li; Paul F Robbins; STEVEN ROSENBERG; Nicholas P Restifo
Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(7):3535-42.
2000: Andrew L Feldman; Nicholas P Restifo; H Richard Alexander; David L Bartlett; Patrick Hwu; Pankaj Seth; Steven Libutti
Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice.
Cancer research 2000;60(6):1503-6.
2000: Willem W Overwijk; Marc R Theoret; Nicholas P Restifo
The future of interleukin-2: enhancing therapeutic anticancer vaccines.
The cancer journal from Scientific American 2000;6 Suppl 1():S76-80.
2000: Vincenzo Bronte; Elisa Apolloni; R Ronca; P Zamboni; Willem W Overwijk; Deborah R Surman; Nicholas P Restifo; Paola Zanovello
Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo.
Cancer research 2000;60(2):253-8.
2000: Deborah R Surman; Mark E Dudley; Willem W Overwijk; Nicholas P Restifo
Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(2):562-5.
2000: Willem W Overwijk; Nicholas P Restifo
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
Critical reviews in immunology 2000;20(6):433-50.
2000: Wolfgang W Leitner; Han Ying; David A Driver; Thomas W Dubensky; Nicholas P Restifo
Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
Cancer research 2000;60(1):51-5.
1999: Wolfgang W Leitner; H Ying; Nicholas P Restifo
DNA and RNA-based vaccines: principles, progress and prospects.
Vaccine 1999;18(9-10):765-77.
1999: Fulvia Terenzi; Michael J deVeer; H Ying; Nicholas P Restifo; Bryan R G Williams; Robert H Silverman
The antiviral enzymes PKR and RNase L suppress gene expression from viral and non-viral based vectors.
Nucleic acids research 1999;27(22):4369-75.
1999: Howard Kaufman; J B Rao; Kari R Irvine; Vincenzo Bronte; STEVEN ROSENBERG; Nicholas P Restifo; K R Irivine
Interleukin-10 enhances the therapeutic effectiveness of a recombinant poxvirus-based vaccine in an experimental murine tumor model.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1999;22(6):489-96.
1999: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Mario Sznol; Susan L Schwarz; Paul J Spiess; John R Wunderlich; Claudia A Seipp; JH Einhorn; Linda Rogers-Freezer; Donald E White
Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.
Journal of immunology (Baltimore, Md. : 1950) 1999;163(3):1690-5.
1999: Han Ying; TZ Zaks; Rongfu Wang; K R Irvine; Udai S Kammula; Francesco M Marincola; Wolfgang W Leitner; Nicholas P Restifo
Cancer therapy using a self-replicating RNA vaccine.
Nature medicine 1999;5(7):823-7.
1999: Kari R Irvine; Maria R Parkhurst; EP Shulman; JP Tupesis; Mary Custer; Christopher E Touloukian; Paul F Robbins; Alicia Gómez Yafal; P Greenhalgh; R P Sutmuller; R Offringa; STEVEN ROSENBERG; Nicholas P Restifo
Recombinant virus vaccination against "self" antigens using anchor-fixed immunogens.
Cancer research 1999;59(11):2536-40.
1999: Vincenzo Bronte; D B Chappell; Elisa Apolloni; Anna Cabrelle; M Wang; P Hwu; Nicholas P Restifo
Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(10):5728-37.
1999: Willem W Overwijk; David Lee; Deborah R Surman; Kari R Irvine; Christopher E Touloukian; Chi-Chao Chan; MW Carroll; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(6):2982-7.
1999: TZ Zaks; D B Chappell; STEVEN ROSENBERG; Nicholas P Restifo
Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition.
Journal of immunology (Baltimore, Md. : 1950) 1999;162(6):3273-9.
1999: JN Cormier; Monica C Panelli; J A Hackett; Maria Bettinotti; Arnold Mixon; John R Wunderlich; Linda L Parker; Nicholas P Restifo; S Ferrone; Francesco M Marincola
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model.
International journal of cancer. Journal international du cancer 1999;80(5):781-90.
1999: Y C Xie; C Hwang; Willem W Overwijk; Z Zeng; M H Eng; James J Mulé; Michael J Imperiale; Nicholas P Restifo; Martin G Sanda
Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.
Journal of the National Cancer Institute 1999;91(2):169-75.
1999: Nicholas P Restifo; STEVEN ROSENBERG
Developing recombinant and synthetic vaccines for the treatment of melanoma.
Current opinion in oncology 1999;11(1):50-7.
1999: D B Chappell; TZ Zaks; STEVEN ROSENBERG; Nicholas P Restifo
Human melanoma cells do not express Fas (Apo-1/CD95) ligand.
Cancer research 1999;59(1):59-62.
1998: STEVEN ROSENBERG; Y Zhai; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Claudia A Seipp; JH Einhorn; B Roberts; Donald E White
Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
Journal of the National Cancer Institute 1998;90(24):1894-900.
1998: MW Carroll; Willem W Overwijk; Deborah R Surman; K Tsung; Bernard Moss; Nicholas P Restifo
Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.
Journal of the National Cancer Institute 1998;90(24):1881-7.
1998: Vincenzo Bronte; M Wang; Willem W Overwijk; Deborah R Surman; Federica Pericle; STEVEN ROSENBERG; Nicholas P Restifo
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
Journal of immunology (Baltimore, Md. : 1950) 1998;161(10):5313-20.
1998: D B Chappell; Nicholas P Restifo
T cell-tumor cell: a fatal interaction?
Cancer immunology, immunotherapy : CII 1998;47(2):65-71.
1998: Nicholas P Restifo; Deborah R Surman; H Zheng; P Palese; STEVEN ROSENBERG; A García-Sastre
Transfectant influenza A viruses are effective recombinant immunogens in the treatment of experimental cancer.
Virology 1998;249(1):89-97.
1998: Willem W Overwijk; A Tsung; Kari R Irvine; Maria R Parkhurst; Theresa J Goletz; K Tsung; MW Carroll; C Liu; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
The Journal of experimental medicine 1998;188(2):277-86.
1998: Deborah R Surman; Kari R Irvine; EP Shulman; T M Allweis; STEVEN ROSENBERG; Nicholas P Restifo
Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization.
Journal of immunological methods 1998;214(1-2):51-62.
1998: STEVEN ROSENBERG; James C Yang; Douglas J Schwartzentruber; Patrick Hwu; Francesco M Marincola; Suzanne Topalian; Nicholas P Restifo; Mark E Dudley; Susan L Schwarz; Paul J Spiess; John R Wunderlich; Maria R Parkhurst; Y Kawakami; Claudia A Seipp; JH Einhorn; Donald E White
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma.
Nature medicine 1998;4(3):321-7.
1997: Kari R Irvine; RS Chamberlain; EP Shulman; Deborah R Surman; STEVEN ROSENBERG; Nicholas P Restifo
Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.
Journal of the National Cancer Institute 1997;89(21):1595-601.
1997: CJ Kim; T Prevette; JN Cormier; Willem W Overwijk; MM Roden; Nicholas P Restifo; STEVEN ROSENBERG; Francesco M Marincola
Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(4):276-86.
1997: Willem W Overwijk; Deborah R Surman; K Tsung; Nicholas P Restifo
Identification of a Kb-restricted CTL epitope of beta-galactosidase: potential use in development of immunization protocols for "self" antigens.
Methods (San Diego, Calif.) 1997;12(2):117-23.
1997: Vincenzo Bronte; MW Carroll; Theresa J Goletz; M Wang; Willem W Overwijk; Francesco M Marincola; STEVEN ROSENBERG; Bernard Moss; Nicholas P Restifo
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(7):3183-8.
1997: Kari R Irvine; RS Chamberlain; EP Shulman; STEVEN ROSENBERG; Nicholas P Restifo
Route of immunization and the therapeutic impact of recombinant anticancer vaccines.
Journal of the National Cancer Institute 1997;89(5):390-2.
1997: MW Carroll; Willem W Overwijk; R S Chamberlain; STEVEN ROSENBERG; Bernard Moss; Nicholas P Restifo
Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a murine tumor model.
Vaccine 1997;15(4):387-94.
1997: Y Zhai; James C Yang; Paul J Spiess; Michael I Nishimura; Willem W Overwijk; B Roberts; Nicholas P Restifo; STEVEN ROSENBERG
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(1):15-25.
1997: J N Cormier; M L Salgaller; T Prevette; KC Barracchini; L Rivoltini; Nicholas P Restifo; STEVEN ROSENBERG; Francesco M Marincola
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.
The cancer journal from Scientific American 1997;3(1):37-44.
1996: Nicholas P Restifo
The new vaccines: building viruses that elicit antitumor immunity.
Current opinion in immunology 1996;8(5):658-63.
1996: R S Chamberlain; MW Carroll; Vincenzo Bronte; Patrick Hwu; S Warren; J C Yang; Michael I Nishimura; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines.
Cancer research 1996;56(12):2832-6.
1996: J B Rao; R S Chamberlain; Vincenzo Bronte; MW Carroll; Kari R Irvine; Bernard Moss; STEVEN ROSENBERG; Nicholas P Restifo
IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(9):3357-65.
1996: Nicholas P Restifo; Francesco M Marincola; Y Kawakami; Jeffery Taubenberger; J R Yannelli; STEVEN ROSENBERG
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy.
Journal of the National Cancer Institute 1996;88(2):100-8.
1996: Nicholas P Restifo
Recombinant anticancer vaccines.
The cancer journal from Scientific American 1996;2(1):16-8.
1996: Bernard Moss; MW Carroll; Linda S Wyatt; Jack R Bennink; Vanessa M Hirsch; S Goldstein; W R Elkins; Thomas R Fuerst; Jeffrey D Lifson; M Piatak; Nicholas P Restifo; Willem W Overwijk; R Chamberlain; STEVEN ROSENBERG; G Sutter
Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.
Advances in experimental medicine and biology 1996;397():7-13.
1996: Kari R Irvine; J B Rao; STEVEN ROSENBERG; Nicholas P Restifo
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):238-45.
1996: P W Chen; M Wang; Vincenzo Bronte; Y Zhai; STEVEN ROSENBERG; Nicholas P Restifo
Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1996;156(1):224-31.
1995: Kari R Irvine; Nicholas P Restifo
The next wave of recombinant and synthetic anticancer vaccines.
Seminars in cancer biology 1995;6(6):337-47.
1995: Francesco M Marincola; Peter Shamamian; Licia Rivoltini; Michael L Salgaller; JN Cormier; Nicholas P Restifo; TB Simonis; David Venzon; Donald E White; D R Parkinson
HLA associations in the antitumor response against malignant melanoma.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(4):242-52.
1995: M Wang; P W Chen; Vincenzo Bronte; STEVEN ROSENBERG; Nicholas P Restifo
Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):139-46.
1995: Licia Rivoltini; K C Barracchini; V Viggiano; Y Kawakami; A Smith; Arnold Mixon; Nicholas P Restifo; Suzanne Topalian; TB Simonis; STEVEN ROSENBERG
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
Cancer research 1995;55(14):3149-57.
1995: Vincenzo Bronte; K Tsung; J B Rao; P W Chen; M Wang; STEVEN ROSENBERG; Nicholas P Restifo
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(10):5282-92.
1995: M Wang; Vincenzo Bronte; P W Chen; Linda Gritz; D Panicali; STEVEN ROSENBERG; Nicholas P Restifo
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4685-92.
1995: Kari R Irvine; B J McCabe; STEVEN ROSENBERG; Nicholas P Restifo
Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4651-7.
1995: Nicholas P Restifo; I Bacík; Kari R Irvine; jon yewdell; B J McCabe; R W Anderson; L C Eisenlohr; STEVEN ROSENBERG; Jack R Bennink
Antigen processing in vivo and the elicitation of primary CTL responses.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(9):4414-22.
1995: M K Jakobsen; Nicholas P Restifo; Peter A Cohen; Francesco M Marincola; L B Cheshire; W Marston Linehan; STEVEN ROSENBERG; Richard B Alexander
Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;17(4):222-8.
1995: B J McCabe; Kari R Irvine; Michael I Nishimura; J C Yang; Paul J Spiess; EP Shulman; STEVEN ROSENBERG; Nicholas P Restifo
Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
Cancer research 1995;55(8):1741-7.
1995: Martin G Sanda; Nicholas P Restifo; J C Walsh; Y Kawakami; William G Nelson; Drew M Pardoll; Jonathan W Simons
Molecular characterization of defective antigen processing in human prostate cancer.
Journal of the National Cancer Institute 1995;87(4):280-5.
1994: Peter Shamamian; M Mancini; Y Kawakami; Nicholas P Restifo; STEVEN ROSENBERG; Suzanne Topalian
Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest.
Cancer immunology, immunotherapy : CII 1994;39(2):73-83.
1994: B R Minev; B J McFarland; Paul J Spiess; STEVEN ROSENBERG; Nicholas P Restifo
Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
Cancer research 1994;54(15):4155-61.
1994: Francesco M Marincola; Peter Shamamian; TB Simonis; Andrea Abati; J Hackett; T O'Dea; Patricia A Fetsch; J Yannelli; Nicholas P Restifo; James J Mulé
Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;16(1):13-23.
1994: C M Lawson; Jack R Bennink; Nicholas P Restifo; jon yewdell; Brian Murphy
Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
Journal of virology 1994;68(6):3505-11.
1994: Francesco M Marincola; S Ettinghausen; Peter A Cohen; L B Cheshire; Nicholas P Restifo; James J Mulé; STEVEN ROSENBERG
Treatment of established lung metastases with tumor-infiltrating lymphocytes derived from a poorly immunogenic tumor engineered to secrete human TNF-alpha.
Journal of immunology (Baltimore, Md. : 1950) 1994;152(7):3500-13.
1994: Nicholas P Restifo; B R Minev; A S Taggarse; B J McFarland; M Wang; Kari R Irvine
Enhancing the recognition of tumour associated antigens.
Folia biologica 1994;40(1-2):74-88.
1993: Eitan Shiloni; S E Karp; Mary Custer; joel shilyansky; Nicholas P Restifo; STEVEN ROSENBERG; James J Mulé
Retroviral transduction of interferon-gamma cDNA into a nonimmunogenic murine fibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor.
Cancer immunology, immunotherapy : CII 1993;37(5):286-92.
1993: Nicholas P Restifo; Y Kawakami; Francesco M Marincola; Peter Shamamian; A Taggarse; F Esquivel; STEVEN ROSENBERG
Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):182-90.
1993: Bert O Neil; Y Kawakami; Nicholas P Restifo; Jack R Bennink; jon yewdell; STEVEN ROSENBERG
Detection of shared MHC-restricted human melanoma antigens after vaccinia virus-mediated transduction of genes coding for HLA.
Journal of immunology (Baltimore, Md. : 1950) 1993;151(3):1410-8.
1993: Y Kawakami; Michael I Nishimura; Nicholas P Restifo; Suzanne Topalian; Bert O Neil; joel shilyansky; J R Yannelli; STEVEN ROSENBERG
T-cell recognition of human melanoma antigens.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(2):88-93.
1993: Nicholas P Restifo; F Esquivel; Y Kawakami; jon yewdell; James J Mulé; STEVEN ROSENBERG; Jack R Bennink
Identification of human cancers deficient in antigen processing.
The Journal of experimental medicine 1993;177(2):265-72.
1993: S E Karp; A Farber; J C Salo; Patrick Hwu; G Jaffe; A L Asher; Eitan Shiloni; Nicholas P Restifo; James J Mulé; STEVEN ROSENBERG
Cytokine secretion by genetically modified nonimmunogenic murine fibrosarcoma. Tumor inhibition by IL-2 but not tumor necrosis factor.
Journal of immunology (Baltimore, Md. : 1950) 1993;150(3):896-908.
1992: S E Karp; Patrick Hwu; A Farber; Nicholas P Restifo; M Kriegler; James J Mulé; STEVEN ROSENBERG
In vivo activity of tumor necrosis factor (TNF) mutants. Secretory but not membrane-bound TNF mediates the regression of retrovirally transduced murine tumor.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(6):2076-81.
1992: Nicholas P Restifo; Paul J Spiess; S E Karp; James J Mulé; STEVEN ROSENBERG
A nonimmunogenic sarcoma transduced with the cDNA for interferon gamma elicits CD8+ T cells against the wild-type tumor: correlation with antigen presentation capability.
The Journal of experimental medicine 1992;175(6):1423-31.
1991: Nicholas P Restifo; F Esquivel; A L Asher; H Stötter; R J Barth; Jack R Bennink; James J Mulé; jon yewdell; STEVEN ROSENBERG
Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(4):1453-9.
1991: A L Asher; James J Mulé; A Kasid; Nicholas P Restifo; J C Salo; C M Reichert; G Jaffe; B Fendly; M Kriegler; STEVEN ROSENBERG
Murine tumor cells transduced with the gene for tumor necrosis factor-alpha. Evidence for paracrine immune effects of tumor necrosis factor against tumors.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(9):3227-34.